What question did this study set out to answer?

This study evaluates PD-L1 expression levels and systemic inflammatory markers to assess their prognostic significance in advanced lung, breast, and head and neck cancers.

June 3, 2026CancersOpen Access

Evaluation of PD-L1 Expression and Systemic Inflammatory Blood Cell Ratios as Prognosticators in Advanced Lung, Breast and Head and Neck Cancers

View Full Paper

Ask AI

Bookmark

Authors

TNTaoufik NedjadiKing Saud bin Abdulaziz University for Health Sciences SASultanah AlBoraieKing Saud bin Abdulaziz University for Health Sciences WAWardah AlghamdiKing Saud bin Abdulaziz University for Health Sciences

Discussion

Member takes

Implication

Retrospective cohort analysis identifies PD-L1 and inflammatory markers' impact on outcomes in cancer patients, suggesting their combined use for improved predictions.

Key Points

This study evaluates PD-L1 expression levels and systemic inflammatory markers to assess their prognostic significance in advanced lung, breast, and head and neck cancers.
Retrospective cohort of 141 patients with lung, breast, and head and neck cancers from 2016 to 2021.
PD-L1 expression analyzed through immunohistochemistry using clone 22C3, with scoring per clinical standards.
Correlation and survival analyses conducted to examine associations between PD-L1 levels, inflammatory markers, and patient outcomes.
PD-L1 positivity was 56.75% in lung cancer, 44% in breast cancer, and 92.85% in head and neck cancer cases.
PD-L1 expression showed no significant association with overall survival across cancers, but was linked to platelet-to-lymphocyte ratio (p=0.036) in lung cancer.
Low PLR correlated with improved survival rates in lung cancer (p=0.007) and breast cancer (p=0.031).

Cite This Study

Nedjadi et al. (2026) studied this question.

synapsesocial.com/papers/6a1fc64adee9eb8c0dce7789 https://doi.org/10.3390/cancers18111819

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort analysis identifies PD-L1 and inflammatory markers' impact on outcomes in cancer patients, suggesting their combined use for improved predictions.

Evaluation of PD-L1 Expression and Systemic Inflammatory Blood Cell Ratios as Prognosticators in Advanced Lung, Breast and Head and Neck Cancers

Discussion

Member takes

Implication

Key Points

Cite This Study

Evaluation of PD-L1 Expression and Systemic Inflammatory Blood Cell Ratios as Prognosticators in Advanced Lung, Breast and Head and Neck Cancers

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider